Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Multiple Ascending Dose Phase 1b/2 Trial to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 Intravenously in Subjects With PNH Naïve to Complement-Inhibitor Treatment

Next Previous
Trial Profile

A Multicenter, Open-label, Multiple Ascending Dose Phase 1b/2 Trial to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 Intravenously in Subjects With PNH Naïve to Complement-Inhibitor Treatment

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omoprubart (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Shanghai Pharmaceuticals Holding

Most Recent Events

  • 31 Aug 2023 According to a CANbridge Pharmaceuticals media release, the company will begin enrolling patients in phase 2 registrational trial in 2H 2023 and clinical trial data from this trial is expected in 2H 2024.
  • 26 Jun 2023 According to a CANbridge Pharmaceuticals media release, CANbridge will hold an investor call to discuss preliminary results. The Chinese-language call will be on Monday, June 26, 11:00 AM Beijing Time. To attend, please go to: https://us02web.zoom.us/webinar/register/WN_wRa8LptzREOVHa-HJQHeQA#/registration. The English language call will be on Tuesday, June 27, 10:00 AM EDT. To attend, please go to: https://us02web.zoom.us/webinar/register/WN_MZ2Wo8xwSLe5q7mVKngJLw#/registration.
  • 26 Jun 2023 Preliminary results presented in the CANbridge Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top